By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Biogen Idec, Inc. (Massachusetts) 

14 Cambridge Center

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-679-2000 Fax: 617-679-2617


SEARCH JOBS
Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit www.biogenidec.com


Key Statistics


Email:
Ownership: Public

Web Site: Biogen Idec
Employees: 1700
Symbol: BIIB
 



Industry
Biotechnology


Collaborations

NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan Corporation PLC  (crohn's & MS)

Dyax Corp.  Antibody phage display





Company News
Biogen Idec (BIIB) Slumps After Patient On Top-Selling Drug Dies 10/22/2014 7:50:14 PM
Biogen Idec (BIIB) Third Quarter 2014 Revenues Increase 37% To $2.5 Billion 10/22/2014 9:47:14 AM
Cubist Pharmaceuticals, Inc. (CBST) Brings In Ex-Biogen Idec (BIIB) Exec For CEO Post 10/20/2014 5:44:38 AM
Biogen Idec (BIIB) And Gretchen Rubin Unveil MS Blueprint™, A New Online Tool To Help People With Multiple Sclerosis Attain Personal Goals 10/15/2014 10:40:53 AM
Largest Biotech IPO Yet Could Be Derailed By Forward Pharma (FWP), Biogen Idec (BIIB) Patent Fight 10/15/2014 9:05:53 AM
5 Boston Biotechs Whose Revenue Is Growing Faster Than Biogen Idec, Inc. (Massachusetts) (BIIB)'s 10/3/2014 4:13:08 PM
Biogen Idec, Inc. (Massachusetts) (BIIB) To Report Third Quarter 2014 Financial Results On October 22, 2014 9/26/2014 8:09:54 AM
Analysts Say Biogen Idec, Inc. (Massachusetts) (BIIB) Must Push Into Gene Therapy To Stay Competitive 9/23/2014 4:43:27 PM
Biogen Idec, Inc. (Massachusetts) (BIIB) Named Global Biotechnology Industry Leader On Dow Jones Sustainability World Index 9/23/2014 10:53:42 AM
Olivier Danos Joins Biogen Idec, Inc. (Massachusetts) (BIIB) As Senior Vice President, Gene Therapy 9/23/2014 9:47:49 AM
12345678910...
//-->